首页> Nature communications> A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.

A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.

导出 OA

翻译打印收藏纠错

第一作者： Eric J,Hsu

第一单位： Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.

作者： Eric J,Hsu ^[1] ; Xuezhi,Cao ^[2] ; Benjamin,Moon ^[1] ; Joonbeom,Bae ^[3] ; Zhichen,Sun ^[4] ; Zhida,Liu ^[3] ; Yang-Xin,Fu ^[5]

作者单位： Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. ^[1] Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Xuezhi.Cao@UTSouthwestern.edu. ^[2] Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. ^[3] Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.;Department of Biomedical Engineering, UT Southwestern Medical Center, Dallas, TX, 75390, USA. ^[4] Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Yang-Xin.Fu@UTSouthwestern.edu.;Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Yang-Xin.Fu@UTSouthwestern.edu. ^[5]